Liposomal Doxorubicin Market experiencing steady growth driven by 2037
The Liposomal Doxorubicin Market was valued at USD 1.6 billion in 2024 and is expected to exceed USD 3.6 billion by 2037, growing at a CAGR of 7% from 2025 to 2037. This sustained growth is attributed to increasing cancer prevalence, patient preference for targeted therapies with fewer side effects, and growing clinical adoption of liposomal drug delivery systems.
Liposomal Doxorubicin Industry Demand